Published in J Immunol on September 06, 2013
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The C5a chemoattractant receptor mediates mucosal defence to infection. Nature (1996) 3.73
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A (1975) 2.21
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol (1999) 1.83
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol (2006) 1.70
Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem (2007) 1.66
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol (2000) 1.59
A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol (2005) 1.58
Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med (1981) 1.57
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol (2001) 1.47
Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol (2011) 1.46
The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology (1982) 1.41
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood (2012) 1.26
Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol (2007) 1.25
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev (2013) 1.22
Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells. Am J Pathol (1979) 1.16
Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Anesthesiology (2006) 1.16
Complement: coming full circle. Arch Immunol Ther Exp (Warsz) (2009) 1.12
Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biological activity. J Immunol (1982) 1.07
Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem (2006) 1.07
Label-free cell-based assays using photonic crystal optical biosensors. Analyst (2011) 1.05
Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. J Immunol (2008) 1.05
Unwelcome complement. Cancer Res (2009) 1.04
A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol (1992) 1.04
Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J Invest Dermatol (2000) 1.00
Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol Chem (2008) 0.99
Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol (2010) 0.98
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (2010) 0.97
Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem (2006) 0.96
Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control. J Immunol (1990) 0.95
Expression and localization of proteins of the complement system in human skin. J Clin Invest (1992) 0.94
C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J Immunol (2012) 0.89
A rapid FPLC method for purification of the third component of human and guinea pig complement. J Immunol Methods (1991) 0.88
Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Am J Pathol (2011) 0.87
Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur J Pharmacol (2007) 0.86
Complement in skin diseases. Acta Dermatovenerol Alp Pannonica Adriat (2011) 0.86
Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol Chem (2010) 0.85
A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res (1996) 0.83
Characterization of tryptic fragments of human complement factor C3. Mol Immunol (1985) 0.82
Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions. J Immunol (2006) 0.81
Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis. Biol Chem (2010) 0.80
Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol Chem (2008) 0.78
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab (2007) 6.91
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe (2011) 5.06
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
Structure of C3b reveals conformational changes that underlie complement activity. Nature (2006) 3.22
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology (2008) 2.85
Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2002) 2.83
Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov (2008) 2.80
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol (2008) 2.80
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood (2007) 2.72
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 2.62
The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
The IRE1alpha-XBP1 pathway of the unfolded protein response is required for adipogenesis. Cell Metab (2009) 2.52
Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 2.48
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med (2003) 2.38
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology (2006) 2.26
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology (2005) 2.18
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clin Chem Lab Med (2014) 2.03
Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol (2011) 2.01
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 1.98
The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One (2011) 1.96
A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol (2007) 1.95
P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. Chem Rev (2010) 1.95
Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal (2010) 1.91
A conformational switch in vinculin drives formation and dynamics of a talin-vinculin complex at focal adhesions. J Biol Chem (2006) 1.90
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol (2003) 1.84
Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol (2005) 1.83
Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol (2010) 1.83
Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther (2011) 1.81
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin. J Biol Chem (2005) 1.79
Analysis of oral microbiota in children with dental caries by PCR-DGGE and barcoded pyrosequencing. Microb Ecol (2010) 1.77
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol (2004) 1.74
The immune protein CD3zeta is required for normal development of neural circuits in the retina. Neuron (2010) 1.74
Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res (2012) 1.73
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem (2006) 1.72
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem (2007) 1.71
7SK snRNP/P-TEFb couples transcription elongation with alternative splicing and is essential for vertebrate development. Proc Natl Acad Sci U S A (2009) 1.71
Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci U S A (2007) 1.71
Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood (2003) 1.68
A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J Am Chem Soc (2008) 1.67
The role of complement in biomaterial-induced inflammation. Mol Immunol (2006) 1.67
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem (2007) 1.66
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes (2008) 1.65
Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics (2007) 1.65
The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol (2010) 1.64
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res (2004) 1.63
Methamphetamine enhances HIV infection of macrophages. Am J Pathol (2008) 1.60
Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science (2010) 1.59
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem (2007) 1.56
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56
FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem (2006) 1.56
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol (2003) 1.56
Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab (2007) 1.55
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood (2014) 1.55